The Year in Cardiovascular Surgery  by Jones, Robert H.
YT
R
D
A
i
2
a
c
c
t
H
f
m
q
•
•
•
•
e
c
q
v
a
o
C
D
I
c
C
a
s
i
h
m
a
v
U
i
I
2
Journal of the American College of Cardiology Vol. 47, No. 10, 2006
© 2006 by the American College of Cardiology Foundation ISSN 0735-1097/06/$32.00
PEAR IN CARDIOLOGY SERIES
he Year in Cardiovascular Surgery
obert H. Jones, MD, FACC
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.02.041urham, North Carolina
c
t
t
o
l
w
i
h
p
b
m
9
e
h
p
r
t
s
(
C
v
e
m
A
t
d
p
l
t
a
y
t
w
a
3
(
b
d
i
i
u
a
icomprehensive review of articles on cardiovascular surgery
n major general and cardiovascular journals published in
005 identified a large number that were scientifically sound
nd broadly relevant. The scientific quality of the 43 articles
hosen as most likely to affect the future practice of cardiovas-
ular specialists made it difficult to identify a single work as
he “outstanding cardiovascular surgical article of 2005.”
owever, the “most valuable topic award” clearly goes to
our articles that distill down and validate multivariable
odel information into bedside risk prediction tools that
uantitate:
The natural history of patients with prior coronary artery
bypass grafting (CABG) using coronary angiography.
Operative mortality and five-year survival in patients
with low ejection fraction (EF) using five clinical vari-
ables.
Major infection after CABG using preoperative variables
with or without intraoperative variables.
Operative risk for aortic and mitral valve surgery using
clinical information.
Careful use of these scores to adjust estimates for differ-
nces in outcomes in care environments that develop (and
are providers who apply) the predictive tool will infuse
uantitative thinking into physician deliberation and pro-
ide patients with information describing personalized risks
nd benefits to inform their deliberations about an
peration.
ORONARY ARTERY DISEASE
elivery of High-Quality CABG Care
nfluence of CABG volume on patient outcomes. Clini-
al data on 27,355 adults voluntarily entered into the
alifornia CABG Mortality Report Program between 1997
nd 1998 were used to examine the influence of hospital-
pecific case volume rates on patient mortality (1). Annual
solated CABG operations ranged from a low of 44 to a
igh of 1,283 among the 68 participating hospitals. The
ultivariable logistic regression model that was used to
djust for baseline patient differences using 22 clinical
ariables performed with a C index of 0.80 in a validation
From the Department of Surgery, Duke Clinical Research Institute, Duke
niversity Medical Center, Durham, North Carolina. Dr. Jones is the principal
nvestigator of the National Institutes of Health-sponsored Surgical Treatment for
schemic Heart (STICH) Failure Trial.o
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006, accepted February 7, 2006.ohort. Adjusted in-hospital patient mortality rates among
he three cohorts stratified into low, medium, and high
ertiles of hospital case volumes were displayed as a function
f percentile of projected patient risk (Fig. 1). The 44
ow-volume hospitals operated on a higher risk population,
ith an expected mortality of 3.25% compared with 2.37%
n the 19 medium-volume hospitals and 1.97% in the
igh-volume hospitals (Table 1). Adjusting for individual
atient-expected risk alone reduced facility level of variance
y 38%; adding hospital volume categories to the regression
odel reduced variance by an additional 61%. Therefore,
9% of the total variance in outcomes across facilities was
xplained by these two factors. As a group, low-volume
ospitals operated less well on more high-risk CABG
atients than hospitals with larger volumes, and these two
elated factors resulted in 157 excess deaths (0.57%) in the
otal 27,355-patient cohort.
Mandatory statewide CABG reporting in California
upported by the California Society of Thoracic Surgeons
STS), the California Chapter of the American College of
ardiology, and the California Medical Association pro-
ided data to compare with the statewide New York CABG
xperience during 1999 to 2001 (2). Coronary artery bypass
ortality was 33% higher in California than New York.
fter adjustment for differences in baseline patient charac-
eristics, 705 excess deaths (29%) of the 2,431 total CABG
eaths in California are explained solely by the greater
revalence of low-volume hospitals in California (3).
If the U.S. rate of excess CABG mortality attributable to
ow-volume CABG delivery has now decreased to one-half
he California rate reported in this study (0.5  0.0029),
nd only 200,000 CABG operations are performed each
ear, then 290 potentially preventable CABG deaths occur
hroughout the U.S. each year (0.0029  0.5  200,000),
hich is equivalent to an annual fatal crash of a large
irliner.
Administrative data were used to compare hospital or
0-day mortality of percutaneous coronary intervention
PCI) and CABG in 42,737 Medicare beneficiaries served
y 15 cardiac specialty hospitals and 82 general hospitals
uring 2000 and 2001 (3). The mean annual CABG volume
n Medicare patients was 118 in general hospitals versus 285
n specialty hospitals (p  0.001). The multivariate model
sed to adjust for fewer coexisting conditions and fewer
cute myocardial infarctions (MIs) among patients treated
n specialty hospitals had a C statistic of 0.74. The adjusted
dds ratio (OR) for death after CABG remained lower in
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May 16, 2006:2094–107 Year in Cardiovascular Surgerypecialty than general hospitals (0.084, p  0.05). That
xcess mortality in general hospitals related to lower case
olumes was confirmed by a case volume stratified analysis
djusted for baseline patient characteristics that showed no
ifference in CABG mortality among specialty and general
ospitals with similar case volumes.
A high CABG case volume maintains team skill among
are providers (just as it does for athletic teams) and explains
he mechanism responsible for the relationship between
igh CABG volume and low mortality. A recent decrease in
otal patients undergoing CABG, resulting in an excess of
ardiac surgeons ready to provide surgical coverage for PCI
n small hospitals, now fuels a trend toward more small-
olume CABG programs. Broader patient access to primary
CI, often used to justify this trend, should instead be
chieved by improving emergency cardiovascular care sys-
ems in the U.S. Our cardiovascular profession must assume
esponsibility for reducing preventable loss of life by making
ur care delivery systems optimally safe.
ost of CABG. CABG costs were $20,672  $241 in
atients operated at five U.S. hospitals compared with
10,373 $123 for 7,319 CABG patients at four Canadian
ospitals (4). U.S. patients were older, were more likely to
igure 1. Adjusted in-hospital mortality rates from 68 California hospitals
tratified by tertiles of coronary artery bypass graft volume into low (LVH),
edium (MVH), and high (HVH) case volumes. Reprinted from Nal-
amothu et al. (1). Copyright © 2005, American Medical Association. All
ights reserved.
able 1. January 1997 to December 1998 CABG Outcomes in
8 California Hospitals Stratified by Low, Medium, and High
ertiles of Case Volume
Low Medium High All
ospitals (n) 44 19 5 68
ABG patients (n) 9,407 9,307 8,641 27,355
ortality (%) 3.4 2.6 1.5 2.5
eaths 320 242 130 692
xpected mortality* 3.25 2.37 1.97 2.53
xcess mortality 1.28 0.40 — —
xcess deaths 120 37 — 157
Derived from multivariable logistic regression model on entire population. Source:a
allamothu et al. (1).
CABG  coronary artery bypass graft.e women, and were discharged from the hospital sooner
han Canadian patients. After correction for these baseline
ifferences, mortality did not differ significantly between the
wo countries, but CABG performed in the U.S. had an
2.5% higher cost than if performed in Canada (p 0.001).
he higher U.S. cost was driven by higher direct and
verhead costs in U.S. hospitals for all expenses except
ursing care (Fig. 2). In this population, women undergoing
ABG had a $2,809 greater cost in the U.S. and $1,057
reater cost in Canada than men (p  0.0001) (5). After
djusting for age and comorbid conditions, female gender
emained associated with a 10% increase in length of stay
p  0.0001), a 97% increase in mortality (p 0.0006), and
7% increase in overall cost (p  0.0001).
atient Selection
rior CABG. The influence of bypass graft patency and
xtensiveness of intrinsic coronary atherosclerosis on subse-
uent survival without repeat revascularization was assessed in
,178 patients with previous CABG using the date of diag-
ostic catheterization as time zero and censoring patients at
ny subsequent cardiac revascularization over a mean interval
f 3 years after catheterization (6). A graft index expressed as a
to 100 number relating directly to observed prognostic
mportance proved to be the third most important predictor of
ubsequent death, and, along with age and presence of heart
ailure, made up 50% of the total prognostic information
Table 2). This graft index was first derived from descriptions
f disease in native vessels and whether myocardial territories
eopardized by intrinsic coronary disease were served by a
atent bypass graft (75% stenosis). When combined with
nformation describing presence or absence of a 75% left
ain stenosis and whether an intact graft conduit was an
nternal mammary artery and not a vein, this extended coro-
ary bypass graft index identified patients with a five-year
urvival that ranged from a low of 50% (patients with all
revious bypass grafts significantly diseased and three-vessel
igure 2. Coronary artery bypass graft costs in U.S. and Canada depicted
s mean U.S. $ by cost center. Reprinted from Eisenberg et al. (4).
opyright © 2005, American Medical Association. All rights reserved.nd left main stenosis) to a high of 95.7% (patients with patent
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Year in Cardiovascular Surgery May 16, 2006:2094–107ative coronary arteries) (Table 3). This coronary bypass graft
ndex provides the first quantitative description of the prog-
ostic content of coronary anatomy information in patients
ith prior CABG.
ace. The influence of race on operative and 12-year
utcomes was retrospectively evaluated in a consecutive
ohort of 304 African-American and 6,073 Caucasian
atients undergoing isolated CABG at a single institution
etween 1991 and 2003 (7). Logistic regression and Cox
ultivariable models were used to adjust for baseline dif-
erences in patient characteristics, and propensity scores
ere used to match the African-American cohort with a
imilar Caucasian cohort. Unadjusted and adjusted opera-
ive mortality was similar in African-American and Caucasian
atients. Propensity-matched cohorts of African-American
nd Caucasian patients also had similar long-term survival
Fig. 3). However, Medicaid status, which is prevalent
mong African Americans, was significant but contributed
nly about 1% of the prognostic information in a Cox model
hat was dominated by patient age and presence of renal
ailure and/or diabetes.
A retrospective study of a cohort of 566,785 white and
4,354 black Medicare beneficiaries undergoing CABG in
able 2. Cox Model for Prediction of All-Cause Death in 3,178
atients Undergoing Coronary Angiography 4.1 Years (Mean)
fter CABG and Followed for 3.0 Years (Mean)
Variable % Information
Hazard
Ratio Indicator
ge 28.6 1.53 Per 10 yrs
eart failure 15.8 1.84  class 2
raft index 14.0 1.01 Per point
iabetes 13.7 1.73 Any type
eripheral vascular
disease
10.5 1.60 Carotid or
iliofemoral
ears since CABG 7.1 1.06 Per yr
entricular gallop 5.6 1.77 Clinical
examination
istory of myocardial
infarction
4.7 1.39 Clinical diagnosis
100
ource: Liao et al. (6).
CABG  coronary artery bypass graft.
able 3. Five-Year Survival Relationship to Coronary Bypass Gra
Coronary Bypass
Graft Index
Native Vessels With
>75% Stenosis
Number of Territor
by Bypass Gra
0% to 74% St
0 0 NA
31 1 1
48 2 2
56 3 3
64 2 1
69 2 0
77 3 2
87 3 1
100 3 0ource: Liao et al. (6).
CABG  coronary artery bypass graft; IMA  internal mammary artery; NA  not a,091 hospitals from 1997 to 2000 confirmed that, after
djustment only for patient characteristics, mortality at 30,
0, and 365 days was 8%, 11%, and 25% higher, respec-
ively, in black than in white patients (8). After adjustment
or hospital effects, the 30- and 90-day mortalities were
imilar, but mortality at 365 days was 70% higher in black
atients. However, zip code data was the only information
vailable to reflect socioeconomic differences. Socioeco-
omic status appears to be a more dominant determinant of
ABG outcome than race.
ow EF. Adding CABG to intensive medical therapy may
ncrease long-term survival benefit to patients with ischemic
ardiomyopathy but at a higher procedure mortality than in
atients with normal left ventricular (LV) function. Demon-
tration of myocardial viability in an underperfused and dys-
unctional myocardial region is widely used to identify patients
or revascularization despite lack of evidence for its discrimi-
atory power (9). Until this question is definitively addressed
y the ongoing STICH trial, balancing CABG operative risk
nd survival benefit against quantitative estimates of survival in
imilar medically treated patients provides the best objective
nformation to counsel patients with ischemic cardiomyopathy
bout the value of revascularization.
Stratification of 55,515 patients from the New York State
ABG registry between 1997 and 1999 into four EF groups
emonstrated the influence of LV dysfunction on in-
ospital and early CABG mortality (10) (Fig. 4). Multiva-
iable analysis in the 2,442-patient subgroup (4.4%) of this
ohort with EF 20% and an in-hospital mortality of 6.5%
dentified older age, MI within 6 h, reoperation, renal failure,
nd hepatic failure as strong additional risk predictors.
A retrospective single-institution study evaluated the
ong-term predictors of survival during a mean follow-up of
.1 years in 544 consecutive patients with an EF25% who
nderwent CABG from 1992 to 2002 (11). A multivariable
ox regression analysis permitted construction of a predic-
ive score for long-term mortality in 360 patients that was
alidated in a set of 184 patients. The five variables included
n the multivariable equation created the acronym HAVOC
or the score, based upon H – heart failure, A – age, V –
dex in Patients With Prior CABG
otected
th
s
5-Year Survival %
With Left
Main >75%
With Intact
IMA Graft
No Left Main or
Intact IMA Graft
NA NA 95.7
NA 88.3 86.2
65.3 86.5 83.7
67.8 87.1 83.7
76.2 80.0 77.7
71.2 NA 78.1
62.9 74.0 70.4
63.3 66.1 63.4
50 NA 60.7ft In
ies Pr
ft Wi
enosipplicable.
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May 16, 2006:2094–107 Year in Cardiovascular Surgeryascular disease, O – operation as emergency, C – chronic
bstructive pulmonary disease using the New York Cardio-
ascular Database definitions (Table 4). The four-level
AVOC score provides estimates of 30-day CABG mor-
ality and subsequent five-year survival. A low HAVOC
core of 1 predicts a 3% 30-day CABG mortality and an
2.3% five-year survival, whereas a high HAVOC score of
predicts a 10.9% 30-day CABG mortality and a 45.5%
ve-year survival. This quantitative tool for assessment of
urgical outcomes in patients with low EF when compared
ith other estimates of risks and benefits expected from
edical treatment alone should assist individual patients
nd their physicians in deciding whether or not to undergo
evascularization for this high-risk condition.
nfection risk. Major infection after CABG increases peri-
perative morbidity and long-term mortality, and no robust
odel exists to predict its occurrence. A search of the STS
atabase identified major infection (septicemia 35%, vein
arvest site 33%, mediastinitis 25%, other 7%) to have
ccurred in 11,636 (3.5%) of 331,429 CABG operations
erformed from January 2002 to December 2003 (12).
ogistic regression was used to identify risk factors and to
enerate and validate two predictive models. One model
igure 3. (Left) Propensity-adjusted survival comparing CABG survival in
oronary artery bypass graft survival in matched African-American (AA)igure 4. In-hospital and early mortality rates stratified by ejection fraction (EF
rom 1997 to 1999. Reprinted from Topokara et al. (10), with permission.ncluded only information known preoperatively. A second
odel included both preoperative and intraoperative char-
cteristics. These two risk scores were developed by simpli-
ying multivariable analysis equations when applied to the
alidation sample performed with a C index of 0.69 when
ased only on preoperative characteristics and 0.70 when
ased on pre- and intraoperative characteristics (Table 5).
he capacity of this tool to predict major CABG infection
ates that ranged from 1% to 16% is certain to be valuable
or more accurately informing patients of their infection risk
nd to focus intensive use of preventive strategies to patients
redicted to have high perioperative infection risk.
edical Therapy
lopidogrel. The common use of clopidogrel in patients
ith acute coronary syndrome assures that decisions must
ften be made about its use in patients for whom CABG
ay later be considered as a therapeutic option. The effect
f preoperative clopidogrel use on perioperative bleeding
as evaluated in 2,359 patients undergoing isolated CABG
t a single center between January 2000 and June 2002 (13).
n this observational study, 415 patients (17.6%) received
lopidogrel before CABG and 1,944 (82.4%) did not.
asian and African-American (AA) patients. (Right) Kaplan-Meier 12-year
aucasian patients. Reprinted from Zacharias et al. (7), with permission.) in patients undergoing coronary artery bypass graft in New York State
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Year in Cardiovascular Surgery May 16, 2006:2094–107lopidogrel use was a strong independent predictor in
ultivariable modeling of all end points related to bleeding
ut did not significantly increase operative mortality.
ropensity-score matched analysis showed that clopidogrel
dministration increased reoperation for bleeding more than
our-fold and transfusion of any blood, multiple units of
lood, or platelets by two-fold. These data strongly advocate
or a management strategy of potential CABG candidates
ith acute coronary syndrome that delays clopidogrel ad-
inistration until coronary angiogram information is avail-
ble to guide the choice of PCI or CABG if revasculariza-
ion is indicated.
able 4. 30-Day Mortality and 5-Year Survival Relationship to H
HAVOC Score HAVOC Equation Value
1 3.18
2 3.19–3.59
3 3.60–4.05
4 4.05
0.43  0.049  0.507
eart Failure
(past or current)
Age (in yrs) Vascular Disease carotid
surgery, 50% stenos
vascular operation, 
absent pulses
ource: DeRose et al. (11).
CABG  coronary artery bypass graft.
able 5. Prediction of Major Infection After CABG Using
nly Preoperative Variables or Preoperative and Intraoperative
ariables
Use Either Score to Obtain Total Points for Patient
Only
Preoperative Variables
Preoperative
and
Intraoperative
1 point Age (for each 5 yrs over 55 yrs) 1 point
4 points BMI 30–40 kg/m2 3 points
9 points BMI 40 kg/m2 8 points
3 points Diabetes 3 points
4 points Renal failure 4 points
3 points Heart failure 3 points
2 points Peripheral vascular disease 2 points
2 points Female gender 2 points
2 points Chronic lung disease 3 points
6 points Cardiogenic shock
2 points Myocardial infarction
4 points Concomitant surgery
Cardiopulmonary bypass 100–199 min 3 points
Cardiopulmonary bypass 200–300 min 7 points
Intra-aortic balloon pump 5 points
Total Points Probability of Infection
0–2 1.1%
3–6 1.2%–1.9%
7–9 2.0%–2.7%
10–12 3.0%–4.0%
13–15 4.5%–6.0%
16–22 6.6%–11.8%
22 12.1%–16.2%a
ource: Fowler et al. (12).
BMI  body mass index; CABG  coronary artery bypass graft.lucose control. The influence of careful hyperglycemic
ontrol during cardiopulmonary bypass was evaluated in
,579 diabetic and 4,701 non-diabetic patients undergoing
ardiac surgery at a single institution between 1999 and
001 (14). Stepwise multivariate logistic regression analysis
as used to correct for differences in baseline characteristics
o assess the importance of keeping peak glucose levels at
ess than 20 mol/l (360 mg/dl) during cardiopulmonary
ypass. A high glucose level during cardiopulmonary bypass
as an independent predictor of in-hospital mortality in
on-diabetic patients (OR 1.12, p 0.0001) and in diabetic
atients (OR 1.20, p 0.0005). These data argue for careful
lucose control during cardiopulmonary bypass.
ostoperative assessment and management. A MED-
INE database search of English-language publications dur-
ng the years 1966 to 2004 yielded only 14 randomized clinical
rials evaluating drug use in 100 or more patients undergoing
ABG that examined outcomes more than one year after
ABG (15).
Aspirin was evaluated in eight randomized clinical trials
hat included 147 to 777 patients treated with at least 320
g of aspirin per day with or without dipyridamole. Aspirin
ppears to be effective in reducing bypass graft occlusion at
2 months after CABG when administered within one day
fter the operation. Evidence is lacking to support the
enefit of aspirin in reducing the incidence of cardiovascular
vents more than one year after CABG.
Three randomized, controlled trials of antilipid agents in
,934 patients suggested that long-term treatment with
ntilipid agents prevented progression of both native coro-
ary artery and coronary graft atherosclerosis and subse-
uent cardiovascular events in CABG patients. None of
hese studies started treatment at the time of surgery, and
nly one of the three trials examined a statin drug.
A single trial of beta-blockers randomized 967 patients to
eceive or not receive a metoprolol regimen begun within
hree weeks after CABG and continued for two years. No
dverse end point was found to be significantly different
etween the two groups at two-year follow-up.
A single calcium-channel blocker trial randomized 120
ABG patients with normal perfusion of the radial artery
OC Score in CABG Patients With Ejection Fraction 0.25
30-Day Mortality 5-Year Survival
3.0% 82.3%
2.9% 78.2%
5.1% 65.5%
10.9% 45.5%
 0.58  0.366
ke, carotid
femoral:
stenosis,
Operation (performed
as emergency)
Chronic obstructive
pulmonary diseaseAV
: stro
is ilio
50%fter one year of treatment with 120 mg daily or oral
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May 16, 2006:2094–107 Year in Cardiovascular Surgeryiltiazem to either continue or suspend further treatment.
our-year follow-up showed no significant difference in
schemic end points.
Only one randomized clinical trial examined the benefit
f angiotensin-converting enzyme inhibition after CABG.
he QUO VADIS study evaluated administration of
uinapril 40 mg daily, which had no effect on the primary
nd point of change in total exercise duration or the
ncidence of ischemia on Holter monitoring. However,
.5% of patients receiving quinapril experienced ischemic
vents such as angina, death, MI, repeat revascularization,
troke, or transient ischemic attack versus 15% of patients
eceiving placebo (p  0.02).
This paper exposes the weakness of the evidence base
vailable to guide postoperative therapy in the CABG
atient. The growing tendency to incorporate medication
se in CABG patients at time of post-CABG discharge as
quality indicator for an entire institution is not only
nsubstantiated by rigorous evidence but potentially dan-
erous to patients. Drugs clearly indicated in patients with
oronary artery disease, such as angiotensin-converting en-
yme inhibitors, beta-blockers, and lipid-lowering agents,
rovide only modest survival benefit per month but may
mpose substantial risk when started in the early postoper-
tive period, when CABG patients are still recovering from
he psychologic and physiological stress of surgery associ-
ted with high circulating catecholamines, hemodilution
nemia, pain medication side effects, sleep and diet disrup-
ion, and general elevation of daily stress responses.
raft patency. An adequately powered Phase III, double-
lind, placebo-controlled trial (PREVENT IV) studied the
fficacy and safety of edifoligide, a E2F transcription factor
ecoy, for prevention of vein graft failure in 3,014 patients
ndergoing primary CABG (16). Vein grafts were treated
x vivo with either edifoligide or placebo in a pressure-
ediated delivery system. A total of 1,920 patients (80%)
eached the end point of either death (n  91) or vein graft
atency assessment by 12- to 18-month follow-up angiog-
aphy (n  1,829). Edifoligide had no primary effect on per
atient graft conduit occlusion, which was 45.2% in the
difoligide group versus 46.3% in the placebo group, on any
econdary angiographic end point, or on the incidence of
ajor cardiac events at one year (6.7% in the edifoligide
roup vs. 8.1% in the placebo group). At one year among
he 1,593 patients who had thoracic artery angiography,
nternal thoracic artery grafts had a lower failure rate than
ein grafts (8% vs. 29%). Despite its negative primary
utcome, this trial remains highly significant as the first
dequately powered prospective evaluation of a clinically
mportant hypothesis related to the intraoperative conduct
f CABG.
perative Conduct
n or off cardiopulmonary bypass. A meta-analysis of 37
andomized clinical trials comparing off- and on-pumpCABG
n 3,369 patients showed no significant differences in short- merm mortality or major morbidity (17). End point differences
uggested that 85,000 patients would need to be randomized to
ddress the end point of 30-day mortality with an 80% power.
owever, off-pump CABG significantly decreased atrial fibril-
ation (AF), transfusion, and other postoperative complica-
ions. Only 20 of these 37 studies reported conversion rates,
hich averaged 8% of off-pump CABG patients converting to
n-pump and 1.7% of on-pump CABG patients converting to
ff-pump. However, no study reported outcomes for the
atient subset requiring conversion. Subsequent analysis by a
ingle-center randomized comparison of off- or on-pump
ABG reported that 20 of the 300 randomized patients
6.7%) converted from off- to on-pump CABG (18). This
onversion subgroup had a 10% operative mortality as well as
igh rates of morbid events.
Another meta-analysis of off-pump CABG surgery also
eported results of 37 randomized clinical trials but included
ix different studies from the prior meta-analysis and also
ncluded separate meta-analysis of 22 observational studies
n 293,617 patients (19). In randomized clinical trials,
ff-pump CABG was associated with reduced AF (OR
.59; 95% confidence interval [CI] 0.46 to 0.77) and
on-significant trends toward reduced 30-day mortality,
troke, and MI. Observational studies showed off-pump
ABG to be associated with reduced 30-day mortality (OR
.72; 95% CI 0.66 to 0.78), stroke (OR 0.62; 95% CI 0.55
o 0.69), MI (OR 0.66; 95% CI 0.50 to 0.88), and AF (OR
.77; 95% CI 0.74 to 0.82). At one to two years, off-pump
ABG was associated with trends toward reduced mortality
s well as increased repeat revascularization.
Therefore, randomized controlled trials confirmed the
eduction of AF reported in observational studies but did
ot find reductions in short-term mortality and morbidity
emonstrated by observational studies. These major differ-
nces resulted primarily from randomized clinical trials
eing reported by intention to treat, whereas observational
tudies typically report outcomes of the operation received
nd thereby overstate the effectiveness of off-pump CABG.
The Merged Cardiac Registry was used to evaluate the
isk of conversion from off- to on-pump CABG in 70,514
solated CABG procedures performed from January 1998 to
arch 2004 in 40 facilities. Cardiopulmonary bypass was
egun and completed on pump in 62,634 patients and
egun off pump in 7,880 patients, of whom 7,424 patients
94.2%) were completed as intended and 456 (5.8%) were
onverted to on-pump (20). A logistic regression model of
actors related to conversion from off- to on-pump CABG
ncluded need for urgent procedure, LV hypertrophy, Ca-
adian Cardiovascular Society Class III or IV angina, prior
ABG, and history of cerebrovascular disease. A higher
ortality and morbidity were observed in patients requiring
onversion compared with the on-pump cohort and the
esidual cohort defined by intention to treat by off-pump
ABG (Table 6). Analyzing patients by intention to treat
howed no significant difference in risk-adjusted operative
ortality, but analyzing the failed off-pump patients sepa-
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Year in Cardiovascular Surgery May 16, 2006:2094–107ately or as part of the cardiopulmonary bypass cohort made
he off-pump CABG appear to have a significantly lower
perative mortality. These data illustrate the importance of
ntention-to-treat analysis when comparing these two
odes of revascularization by CABG.
A well-designed prospective observational study was con-
uced by the Canadian Off-pump CABG Registry Inves-
igators among 13 high-volume cardiac centers and 42
urgeons across Canada between March 12, 2002, and
ecember 31, 2002 (21). The time and reason for conver-
ion from off-pump to on-pump were prospectively re-
orded when any patient received cardiopulmonary bypass
uring an intended off-pump CABG. Standard definitions
ere prospectively applied uniformly by all centers. Tele-
hone follow-up at one year was complete in 97.7% of all
atients. A prospective sample size of 1,600 patients was
dentified to be sufficient to detect a 1.5% decrease in
ne-year mortality at a reasonable level of significance. A
tepwise multivariable logistic regression analysis was per-
ormed to identify a population of patients with a 1:1 ratio
f benefit anticipated from off- or on-pump CABG. Over
0 months ending in December 2002, 3,250 consecutive
solated CABG patients (1,656 off-pump and 1,693 on-
able 6. Observed Mortality and Morbidity in 70,514 Isolated
ABG Operations Performed in 40 Centers, 1998–2004
Outcome
Off-Pump
CABG (%)
Off-Pump Converted to
On-Pump CABG (%)
On-Pump
CABG (%)
ortality 1.6 10.3 3.0
eoperation for
bleeding
1.5 6.6 2.4
enal failure 6.9 18.9 5.4
troke 1.0 6.6 2.5
ulmonary failure 3.7 16.7 6.5
astrointestinal
complication
1.4 3.0 1.8
onversion different than on- or off-pump CABG (p 0.001) for all variables except
astrointestinal problem, which was different only from off-pump CABG (p  .011).
ource: Jin et al. (20).
CABG  coronary artery bypass graft.
Table 7. Propensity Score-Matched In-Hospit
Off-Pump CAB
(n  1,233)
In-hospital
Mortality (%) 1.5
Stroke (%) 0.8
Myocardial infarction (%) 3.0
Acute renal disease* 0.4
Graft complete (mean  SD) 2.62  1.0
One year†
Mortality (%) 3.5
Stroke (%) 1.4
Myocardial infarction (%) 3.9
Renal dialysis* (%) 1.1
Coronary angiogram (%) 3.3
Coronary revascularization (%) 1.9
*Patients receiving renal dialysis at baseline were excluded fro
months after surgery. Source: Lamy et al. (21).
CABG  coronary artery bypass grafts; CI  confidence interump) were entered into the study and reported by inten-
ion to treat. More bypass grafts were completed in on-
ump patients. No significant differences were observed in
he rates of in-hospital mortality or stroke, but MI and acute
enal disease were higher in off-pump patients (Table 7). At
ne year, the only significant difference was a lower stroke
ate in the off-pump cohort. No preoperative characteristics
learly defined subgroups most likely to benefit from a
pecific operative approach.
The exemplary methodology of this study serves as a
emplate for the design of any future prospective observa-
ional study. However, the 0.2% difference in-hospital
avoring off-pump CABG and the 0.4% difference in
ne-year mortality favoring on-pump CABG suggest that a
ery large sample size will be needed to show differences
ith statistical certainty. Such a trial would be feasible only
ith a large national registry such as the STS database.
eed for concomitant mitral repair for insufficiency. A
etrospective review of 251 patients with 3 ischemic mitral
egurgitation undergoing CABG between 1991 and 2001
ncluded 31 patients who had concomitant mitral annulo-
lasty performed at the discretion of the operating surgeon
22). Parametric multiphase hazard regression models were
sed to correct for differences in other baseline and operative
haracteristics. The performance of a mitral annuloplasty at
he time of CABG reduced the degree of mitral regurgita-
ion but did not predict greater long-term survival.
ostoperative Assessment and Management
K-MB prognosis. Uniform prospective electrocardiogra-
hy and creatine kinase-MB fraction (CK-MB) was mon-
tored in 800 CABG patients who had participated in the
REVENT IV study to reflect myocardial injury at CABG
or predicting later death or LV dysfunction (23). Multiple
ogistic regression models confirmed increased cardiopul-
onary bypass time to be the strongest predictor of 30-day
ortality or early severe LV dysfunction. Peak CK-MB100
g/ml and age were the other two significant variables. Q-wave
d One-Year Outcomes
On-Pump CABG
(n  1,233) OR (95% CI) p Value
1.7 0.90 (0.48–1.69) 0.750
1.6 0.49 (0.23–1.06) 0.072
1.5 2.09 (1.18–3.69) 0.011
1.4 0.23 (0.08–0.69) 0.009
3.36  0.9 0.001
3.9 0.90 (0.59–1.38) 0.643
2.7 0.49 (0.27–0.90) 0.021
3.0 1.32 (0.85–2.06) 0.215
2.1 0.51 (0.25–1.02) 0.058
3.8 0.86 (0.55–1.33) 0.502
1.9 1.02 (0.56–1.86) 0.936
lysis. †Includes any event from the date of surgery up to 12al an
G
m anaval; OR  odds ratio.
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May 16, 2006:2094–107 Year in Cardiovascular SurgeryI was not an independent predictor of subsequent death or
evere LV failure. These are the first data to show prospective
onitoring of CK-MB after CABG to add independent
rognostic information after clinical and electrocardiographic
utcome markers are considered.
perative stroke influence on survival. The Northern
ew England Cardiovascular Disease Study Group exam-
ned the influence of stroke (defined as a new fixed neuro-
ogic defect persisting at least 24 h after surgery) on 10-year
ll-cause mortality survival derived from the National Death
ndex on 35,733 consecutive patients undergoing isolated
ABG surgery from 1992 to 2001 (24). Stroke occurred in
75 (1.61%) of the 35,733 patients undergoing isolated
ABG. Patients with strokes were about five years older,
ore likely to be women; slightly smaller; and have lower
Fs, more comorbidities, three-vessel disease, diabetes,
enal disease, and urgent need for surgery than patients who
id not sustain a stroke. The annual incidence of death over
0 years was 3.86 per 100 person-years in the entire cohort.
fter adjusting for the differences in baseline patient char-
cteristics, the hazard ratio for increased death in patients
ustaining a stroke at CABG was 3.2 (p  0.001). The
nadjusted survival curve defines the actual subsequent
eath burden incurred by patients who sustain an early
ostoperative stroke. These data offer a quantitative com-
ined end point of death and predicted death at a subse-
uent time that should prove useful in future CABG
utcome studies, because not only is the added death burden
eal, but the stroke also reduces quality of life remaining
efore this hastened death (Fig. 5).
uration of AF therapy. From a consecutive cohort of
,206 patients, the 129 patients in whom new AF after
ABG successfully reverted to sinus rhythm in the postop-
rative period were prospectively randomized at discharge to
eceive anti-arrhythmic therapy for one, three, or six weeks
25). Beta-blockers were continued in all patients receiving
hese agents before surgery. Discontinuation of the specific
edication used to treat the perioperative episode of AF (most
ommonly amiodarone and beta-blockers) did not lead to
ignificant difference in recurrence of AF among the three
igure 5. Ten-year adjusted survival in patients who undergo CABG
omplicated by stroke (stroke) or without neurologic deficit persisting 24 hr
no stroke). Reprinted from Dacey et al. (24), with permission from the
ociety of Thoracic Surgeons.roups. These data suggest that anti-arrhythmic therapy for
erioperative AF for as short as one week may be appropriate.
OMPARISON OF CABG AND PCI
eta-analysis of recent trials. The primary clinical end
oint of death, MI, and stroke at one year was reported from
database composed of individual data on 1,533 patients
nrolled in four randomized trials comparing CABG and PCI
ith bare metal stenting (Arterial Revascularization Strategies
tudy (ARTS), Stent or Surgery [SOS] trial, Argentine
andomized Trial of PCI Versus CABG in Multivessel
isease 2 [ERACI-2], and Medicine, Angioplasty, or Surgery
tudy 2 [MASS-2]) (26). The primary end point of death,MI,
r stroke at one year did not differ between a stenting or
ABG revascularization strategy, but repeat revascularization
rocedures occurred more frequently in patients allocated to
tenting (18% vs. 4.4%, p  0.001) (Fig. 6).
he ARTS trial 5-year outcomes. During five-year
ollow-up of the 1,205 patients in the ARTS trial, death
ccurred in 48 (8.0%) of 600 patients with multi-vessel
isease randomized to receive bare-metal stents and in 46
7.6%) of the 605 patients randomized to CABG (p 0.83)
27). Among 208 diabetic patients, mortality was 13.4% in
he stent group and 8.3% in the CABG group (p  0.27).
he incidence of repeat revascularization was 30.3% in the
tent group and 8.8% in the CABG group (p  0.001).
ew York outcomes. Three-year death and subsequent
evascularization events were compared in 59,314 patients
ith multi-vessel disease who underwent either CABG
n  37,212, 65%) or PCI with stenting (n  22,102, 35%)
n New York state between January 1, 1997, and December
1, 2000 (28). Rates of adverse outcomes were adjusted by
roportional hazard methods to account for differences in
aseline markers of severity of illness. The median
ollow-up was 1.9 years in the CABG group and 1.6 years
n the PCI group. After adjustment for severity of illness,
ABG was associated with a significantly higher likelihood
f survival in all anatomic subgroups (Fig. 7).
These New York registry results argue for use of more
estrictive criteria for PCI and more liberal referral of patients
o CABG for revascularization, especially those with severe
hree-vessel disease. These data also demonstrate the impor-
ance of continued surveillance of outcomes when applying
andomized trial data to the general patient population.
ARDIAC VALVE SURGERY
eed for Valve Replacement
symptomatic aortic stenosis. A systolic velocity of 4
/s by Doppler echocardiography identified 622 patients
ith isolated asymptomatic aortic stenosis who did not
ndergo surgery at the time of initial evaluation (29). This
roup, with an average age of 72  11 years and 62% men,
as followed for 5.4  4.0 years. The probability of
emaining free of symptoms and alive while unoperated was
8
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Year in Cardiovascular Surgery May 16, 2006:2094–1072% at one year, 67% at two years, and 33% at five years
Fig. 8). Significant independent predictors of death on Cox
odeling were advanced age (p  0.0001), chronic renal
ailure (p  0.004), inactivity (p  0.001), and elevated aortic
alve velocity (p  0.03). Sudden death without preceding
ymptoms occurred in 11 (4.1%) of 270 unoperated patients.
ecause the risk of sudden death in this population is equiv-
lent to that expected for aortic valve replacement, this study
upports aggressive use of surgical management for asymptom-
tic patients with significant aortic stenosis.
itral regurgitation. Outcomes were evaluated in 456
atients prospectively defined to have asymptomatic organic
itral regurgitation, defined as a regurgitant volume of 66
40 ml per beat and an effective regurgitant orifice of 44
7 ml/m2, enrolled at a single institution between 1991 and
000 (30). The population, with a mean age of 63  14
ears, 63% men, and EF mean of 70  8, was followed for
mean of 2.7  2.9 years under medical management (n 
24) or by medical management followed by surgery (mean
nterval 1.2  2.0 years) in 203 patients followed 5.1  2.9
igure 6. Incidence of adverse cardiovascular events and repeat revasculari
andomized trials comparing stenting with coronary artery bypass grafti
ermission from American Association for Thoracic Surgery.ears. Independent determinants of survival included ad- vanced age, diabetes, and large effective regurgitant orifice.
fter adjustment for age, gender, diabetes, AF, and Char-
eson comorbidity index at baseline, the effective regurgitant
rifice independently predicted survival with an adjusted
isk ratio from any cause of 1.2 for each 10 ml/m2 increment
p  0.01). Regurgitant volume was not independently
redictive of all-cause death. After multivariate analysis
djusted for age, gender, diabetes, AF, and effective regur-
itant orifice, EF and Charleson comorbidity index, surgery
ecreased risk of death (hazard ratio 0.35, p  0.01).
igure 9 illustrates Kaplan-Meier estimates of rates of death
rom a cardiac cause among medically treated patients with
symptomatic mitral regurgitation stratified by effective
egurgitant orifice that quantitate the maximal survival
enefit possible with surgical intervention in asymptomatic
atients as a function of duration of time after assessment.
Two cardiologists at a single center screened 682 consec-
tive patients between 1995 and 2002 with significant
itral regurgitation and systolic LV dysfunction on echo-
ardiography who were identified to be candidates for mitral
procedures during one-year follow-up in 1,533 patients enrolled in four
I  myocardial infarction. Reprinted from Mercado et al. (26), withzationalve annuloplasty (MVA). After surgical evaluation, 126
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May 16, 2006:2094–107 Year in Cardiovascular Surgeryatients underwent MVA (31). Propensity score derivation
dentified that age, EF, and LV dimension had been used to
elect patients for MVA. Mitral valve annuloplasty status
reated as a time-dependent covariate was not an indepen-
ent predictor of clinical outcome.
perative Risk
rediction of operative risk. The Society of Cardiotho-
igure 7. Adjusted Kaplan-Meier survival curves among New York pa-
ients with multi-vessel coronary artery disease. (A) Patients with two-
essel disease without involvement of the left anterior descending (LAD)
rtery. (B) Patients with two-vessel disease with involvement of the
roximal LAD artery. (C) Patients with three-vessel disease with involve-
ent of the proximal LAD artery. Values and percentages at one, two, and
hree years adjusted for baseline characteristics. Reprinted from Hannan et
l. (28), with permission.acic Surgeons of Great Britain and Ireland data from
m
R6,679 patients who underwent heart valve surgery between
995 and 2000 were used to develop a multivariate model to
redict in-hospital mortality in patients undergoing mitral
nd/or aortic valve operations (32). This model performed
ell with a C index of 0.77 when validated in 16,160 other
atients undergoing heart valve surgery from 2000 to 2003.
simplified risk score (to use with a lookup table) devel-
ped only from 2003 data provides a valuable bedside tool
hat permits clinicians to predict operative risks for individ-
al patients undergoing aortic or mitral valve surgery over a
ange from mortality of 0.2% to more than 50% (Table 8).
nfluence of race on risk. The Society of Thoracic Sur-
eons National Cardiac Database was used for retrospective
eview of 3,137 black and 46,249 white patients who
nderwent isolated mitral or aortic valve replacement from
999 to 2002 (33). After adjustment for risk factors, black
ace was not a significant predictor of operative mortality
ut was associated with increased risk of morbidity.
isks of reoperation. A single institution compared out-
omes of 162 patients undergoing reoperative aortic valve
eplacement with 2,290 primary aortic valve replacements
igure 8. Survival free of symptoms or aortic valve surgery in asymptomatic
atients. Reprinted from Pellika et al. (29), with permission.
igure 9. Kaplan-Meier estimates of mean ( SE) rates of death from cardiac
auses among patients with asymptomatic mitral regurgitation under medical
anagement stratified to reflect the effective regurgitant orifice (ERO).
eprinted from Enriquez-Sarano et al. (30), with permission.
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Year in Cardiovascular Surgery May 16, 2006:2094–107ith or without CABG between 1993 and 2001 (34). Early
ortality for reoperative aortic valve replacement was 5%
ompared to 3% (p  0.20) for primary aortic valve
eplacement. Multivariate predictors for early mortality were
rosthetic valve endocarditis, advanced preoperative func-
ional class, peripheral vascular disease, and decreased LV
F. After adjustment by multivariable modeling, there was
o difference in early mortality between the reoperative and
rimary aortic valve replacement groups. These data support
he expanded use of bioprosthetic valves at a younger age
ecause the mortality burden of repeat aortic valve replace-
ent now approaches that of the primary operation.
rosthetic Valve Failure
ublished and unpublished data confirm that outlet struc-
ure fractures have occurred often with fatal outcomes in
33 (0.7%) of the 86,000 Björk-Shiley convexoconcave
rosthetic heart valves implanted (35). Fractures continue to
ccur at a rate of 0.1% per year, so that risk of valve
eplacement now typically exceeds risk of sudden death
ssociated with valve failure. Asymptomatic patients en-
ountered with a Björk-Shiley prosthetic heart valve of
nknown type should be carefully risk stratified using the
mplanted valve serial number to assess their individualized
isk of acute valve failure for comparison with the risk of a
0% median overall in-hospital mortality for elective repeat
itral valve replacement.
alve size match to patient size. A single-center study
valuated whether aortic valve prosthesis size relative to
atient body size influenced functional recovery after aortic
alve replacement using the Duke Activity Status Index
ompleted before (n  1,108) and after (n  1,014) aortic
alve replacement (36). Most patients improved functional
apacity after operation, and neither indexed area (p 0.94)
or standardized orifice size (p  0.96) of the prosthetic
alve inserted were predictors of functional recovery after
ortic valve replacement.
URGERY FOR AF
he efficacy of left atrial radiofrequency ablation during
itral valve surgery in patients with chronic AF was
ssessed in a randomized double-blind trial at a single
nstitution between December 2001 and November 2003
37). A history of uninterrupted AF for six months was
resent in all 97 patients randomly assigned to undergo
itral valve surgery with (n  48) or without (n  49)
blation. Sinus rhythm was present one year after surgery in
0 (44.4%) of 45 ablated patients and in 2 (4.5%) of 44
atients with mitral valve surgery alone (p  0.001).
econdary functional and activity capacity assessments
howed improvement in the ablation cohort without an
ncrease in postoperative mortality or morbidity. mURGERY FOR HYPERTROPHIC
BSTRUCTIVE CARDIOMYOPATHY
he determinants of survival over a mean of 7.7  5.2 years
fter surgical myectomy for obstructive hypertrophic cardio-
able 8. Prediction of Operative Risk of Aortic and Mitral
alve Surgery
Preoperative
Characteristic Magnitude Weight
Risk
Score
ge (yrs) 50–59 1
60–69 2
70–79 4
79 5
emale 1
MI 20 kg/m2 2
alve operation Mitral 1
Aortic and mitral 2
ricuspid surgery Concomitant 3
ABG surgery Concomitant 2
enal failure Creatinine 200 mol/l 3
With dialysis 5
rrhythmias Atrial fibrillation/heart block 1
Ventricular tachycardia fibrillation 2
ypertension 1
iabetes 1
jection fraction 30–50 1
30 4
urgical priority Urgent 2
Emergency 7
rior cardiac
operation
One 3
Two or more 4
otal risk score Use to calculate mortality
Total Risk Score Mortality
0 0.2%
1 0.4%
2 0.6%
3 1.0%
4 1.4%
5 2.1%
6 3.0%
7 4.1%
8 5.5%
9 7.3%
10 9.3%
11 11.7%
12 14.3%
13 17.2%
14 20.2%
15 23.5%
16 26.7%
17 30.1%
18 33.4%
19 36.6%
20 39.7%
21 42.6%
22 45.5%
23 48.1%
24 50.6%
25 52.9%
As defined by the Society of Cardiothoracic Surgeons of Great Britain and Ireland.
ource: Ambler et al. (32).
BMI  body mass index; CABG  coronary artery bypass graft.yopathy were assessed in 338 adult patients (age 47  14
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May 16, 2006:2094–107 Year in Cardiovascular Surgeryears, 60% men) at a single institution between 1978 and
002 (38). All patients had a maximal septal thickness of at
east 13 mm and a preoperative LV outflow gradient of 66
32 mm Hg. Operative deaths occurred in five (1.5%) of
atients. Multivariable Cox regression analysis identified
he five predictors of overall mortality to be advanced age,
eft atrial diameter 46 mm, female gender, concomitant
ABG, and history of preoperative AF. Long-term survival
as 98  1% at one year, 95  1% at 5 years, and 83  3%
t 10 years.
omparison of myectomy and alcohol ablation. A
ingle-center retrospective study comparing septal myec-
omy to alcohol ablation was conducted in 150 symptomatic
dults with hypertrophic obstructive cardiomyopathy be-
ween November 1998 and December 2003 (39). Surgical
yectomy was performed in 90 patients referred directly for
he procedure and in five other patients after failed at-
empted alcohol ablation. A concomitant procedure was
erformed in 47 of these patients. The 54 patients who
eceived alcohol ablation and the 48 surgical patients who
ad an isolated myectomy had a mean follow-up of 2.2 years
fter the procedure. There were five late deaths after alcohol
blation and one after myectomy. No significant difference
as observed in after-intervention septal thickness or free-
om from after-intervention pacing. However, three-year
reedom from pacing was 88% in the surgically treated
atients compared with 59% in the ablation-treated pa-
ients. Until larger studies are available, surgical myectomy
hould be considered the standard to which alcohol ablation
ust be compared.
URGERY FOR CONGENITAL HEART DISEASE
ardiopulmonary Bypass in Children
resh compared to reconstituted blood for prime. A
ingle-center randomized, double-blind controlled trial of
ardiopulmonary bypass circuit priming with fresh (96
atients) or reconstituted (104 patients) blood was con-
ucted in children 1 year of age (40). The group that
eceived reconstituted blood had the shorter stay in the
ntensive care unit (70.5 h vs. 97 h, p  0.04) and a smaller
umulative fluid balance at 48 h. Bleeding appeared similar
n both groups. The use of fresh whole blood for cardiopul-
onary bypass in children provides no advantage over a pump
rime using packed red blood cells and fresh-frozen plasma.
anagement of children with C4A deficiency. A single
tudy was conducted in 116 children lacking complement
omponent C4A and susceptible to capillary leak syndrome
uring cardiopulmonary bypass (41). Three (5%) of 58
atients given C4A-rich plasma priming of the bypass
ircuit had capillary leak syndrome, compared with 56
97%) of patients given C4A free plasma (p  0.0001). A
igh concentration of inflammatory markers occurred post-
peratively in patients with capillary leak syndrome. C4A-
ich plasma priming appears to reduce the incidence of
apillary leak syndrome after cardiopulmonary bypass by carkedly preventing the increase in activated C4 and by
ttenuating the increase in other inflammatory mediators.
utcomes of Surgery
nfluence of case volume. Among the 29 pediatric hospi-
als of the Child Health Corporation of America, 87
urgeons performed 801 Norwood procedures for hypoplas-
ic left heart syndrome from January 1998 to December
001 (42). Total institutional Norwood operation volumes
veraged 5.15 (range 2 to 109). Survival ranged from 25% to
00% among institutions. The average number of Norwood
perations per surgeon was 10.7  14 over the four-year
eriod. The overall operative survival rate to hospital dis-
harge was 68%. Stepwise linear regression showed hospital
ase volume to relate to survival (p 0.02), but surgeon case
olume did not.
ntracoronary ultrasound late after arterial switch operation.
he status of reimplanted coronary arteries was evaluated by
ardiac catheterization and intravascular ultrasound per-
ormed in 22 asymptomatic children (median age 9.5 years)
fter arterial switch operation (interval range 5 to 12.6 years)
43). Coronary angiography identified a single significant
tenosis of the right coronary ostium. Quantitative ultra-
ound analysis of 37 coronary artery segments in 20 children
howed some degree of intimal proliferation in 33 of 37
oronary arteries (89%). Significant intimal proliferation
0.3 mm) was observed in 10 of the 20 patients. Signs of
evelopment of early atherosclerosis in reimplanted coronary
rteries will require future monitoring to assess disease progres-
ion and the likelihood of occurrence of late coronary events.
TATUS REPORT OF MAJOR ONGOING RANDOMIZED
LINICAL TRIALS IN CARDIAC SURGICAL PATIENTS
utcomes Following Myocardial Revascularization: On
nd Off Cardiopulmonary Bypass (ROOBY Trial).
SPONSOR: Veterans Affairs Cooperative Study.
PRINCIPAL INVESTIGATOR: Frederick L. Grover, MD
frederick.grover@uchsc.edu).
HYPOTHESIS: In properly selected patients, 30-day and
ne-year mortality and morbidity are equivalent when CABG
s conducted with or without cardiopulmonary bypass.
ENROLLMENT: 1,763 of 2,200 patients enrolled by 17
.S. Veterans Affairs hospitals.
urgical Treatment for Ischemic Heart Failure (STICH-
rial).
SPONSOR: National Institutes of Health.
PRINCIPAL INVESTIGATOR: Robert H. Jones, MD
jones060@mc.duke.edu).
HYPOTHESIS 1:Coronary artery bypass grafting combined
ith intensive medical therapy improves long-term survival
ompared to medical therapy alone in 1,000 patients with
V EF 0.35 and CAD amenable to CABG.
HYPOTHESIS 1 ENROLLMENT: 636 of 1,200 patients
nrolled by 83 sites worldwide; completion expected De-
ember 2006.
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Year in Cardiovascular Surgery May 16, 2006:2094–107HYPOTHESIS 2: Adding surgical ventricular restoration to
ABG and medical therapy improves survival free of
ardiac hospitalization in 1,000 patients with LVEF 0.35,
AD amenable to CABG, and dominant anterior akinesia
r dyskinesia.
HYPOTHESIS 2 ENROLLMENT: 1,000 patients, completed
anuary 24, 2006, at 96 sites worldwide.
uture Revascularization Evaluation in Patients With
iabetes Mellitus: Optimal Management of Multivessel
isease (FREEDOM) Trial.
SPONSOR: National Heart, Lung, and Blood Institute.
PRINCIPAL INVESTIGATOR: Valentin Fuster, MD, PhD
valetin.fuster@mssm.edu).
HYPOTHESIS: In 2,400 diabetic patients with multi-vessel
isease amenable to CABG and PCI and indication for
evascularization, either CABG or PCI will be superior in
reventing death, nonfatal MI, and stroke.
ENROLLMENT: 60 of 2,400 patients enrolled by 9 clinical
ites.
cknowledgment
r. Jones acknowledges Vanessa Moore with appreciation
or her skill in organization and presentation of information
hat is apparent in the tables and her intense motivation that
ermitted this manuscript to be completed in a brief interval
fter the close of 2005.
eprint requests and correspondence: Dr. Robert H. Jones,
uke Clinical Research Institute, P. O. Box 17969, Durham,
orth Carolina 27715. E-mail: jones060@mc.duke.edu.
EFERENCES
1. Nallamothu BK, Saint S, Hofer TP, Vijan SV, Eagle KA, Bernstein
SJ. Impact of patient risk on the hospital volume-outcome relationship
in coronary artery bypass grafting. Arch Intern Med 2005;165:333–7.
2. Carey JS, Danielsen B, Gold JP, Rossiter SJ, for the California Cardiac
Surgery Initiative. Procedure rates and outcomes of coronary revascu-
larization procedures in California and New York. J Thorac Cardio-
vasc Surg 2005;129:1276–82.
3. Cram P, Rosenthal GE, Vaughan-Sarrazin MS. Cardiac revascular-
ization in specialty and general hospitals. N Engl J Med 2005;352:
1454–62.
4. Eisenberg MJ, Filion KB, Azoulay A, Brox AC, Haider S, Pilote L.
Outcomes and cost of coronary artery bypass graft surgery in the
United States and Canada. Arch Intern Med 2005;165:1506–13.
5. Bestawros A, Filion KB, Haider S, Pilote L, Eisenberg MJ. Coronary
artery bypass graft surgery: do women cost more? Can J Cardiol
2005;21:1195–200.
6. Liao L, Kong DF, Shaw LK, et al. A new anatomic score for prognosis
after cardiac catheterization in patients with previous bypass surgery.
J Am Coll Cardiol 2005;46:1684–92.
7. Zacharias A, Schwann TA, Riordan CJ, Durham SJ, Shah A, Habib
RH. Operative and late coronary artery bypass grafting outcomes in
matched African-American versus Caucasian patients. J Am Coll
Cardiol 2005;46:1526–35.
8. Konety SH, Vaughan-Sarrazin MS, Rosenthal GE. Patient and
hospital differences underlying racial variation in outcome after coro-
nary artery bypass graft surgery. Circulation 2005;111:1210–6.
9. Chareonthaitawee P, Gersh BJ, Araoz PA, Gibbons RJ. Revascular-
ization in severe left ventricular dysfunction. The role of viability
testing. J Am Coll Cardiol 2005;46:567–74.0. Topokara VK, Cheema FH, Kesavaramanujam S, et al. Coronary
artery bypass grafting in patients with low ejection fraction. Circula-
tion 2005;112 Suppl I:I344–50.
1. DeRose JJ, Toumpoulis IK, Balaram SK, et al. Preoperative prediction
of long-term survival after coronary artery bypass grafting in patients
with low ventricular ejection fraction. J Thorac Cardiovasc Surg
2005;129:314–21.
2. Fowler VG, O’Brien SM, Muhlbaier LH, Corey GR, Ferguson TB,
Peterson ED. Clinical predictors of major infections after cardiac
surgery. Circulation 2005;112 Suppl I:I358–65.
3. Kapetanakis EI, Medlam DA, Boyce SW, et al. Clopidogrel administration
prior to coronary artery bypass grafting surgery: the cardiologist’s panacea or
the surgeon’s headache? Eur Heart J 2005;26:576–83.
4. Doenst T, Wijeysundera D, Karkouti K, et al. Hyperglycemia during
cardiopulmonary bypass is an independent risk factor for mortality in
patients undergoing cardiac surgery. J Thorac Cardiovasc Surg 2005;
130:1144–50.
5. Okrainec K, Platt R, Pilore L, Eisenberg MJ. Cardiac medical therapy
in patients after undergoing coronary artery bypass graft surgery. A
review of randomized controlled trials. J Am Coll Cardiol 2005;45:
177–84.
6. Alexander JH, for the PREVENT IV Investigators. Efficacy and safety
of edifoligide, an E2F transcription factor decoy, for prevention of vein
graft failure following coronary artery bypass grafting. JAMA 2005;
294:2446–54.
7. Cheng DC, Bainbridge D, Martin JE, Novick RJ, for the Evidence-
based Perioperative Clinical Outcomes Research Group. Does off-
pump coronary artery bypass reduce mortality, morbidity, and resource
utilization when compared with conventional coronary artery bypass?
A meta-analysis of randomized trials. Anesthesiology 2005;102:188–
203.
8. Legare JF, Buth KJ, Hirsh GM. Conversion to on pump from
OPCAB is associated with increased mortality: results from a random-
ized controlled trial. Euro J Cardiothorac Surg 2005;27:296–301.
9. Wijeysundera DN, Beattie WS, Djaiani G, et al. Off-pump coronary
artery surgery for reducing mortality and morbidity: meta-analysis of
randomized and observational studies. J Am Coll Cardiol 2005;46:
872–82.
0. Jin R, Hiratzka LF, Grunkemeier GL, Krause A, Page US. Aborted
off-pump coronary artery bypass patients have much worse outcomes
than on-pump or successful off-pump patients. Circulation 2005;112
Suppl I:I332–7.
1. Lamy A, Farrokhyar F, Kent R, et al., for the Canadian Off-pump
CABG Registry Investigators. The Canadian off-pump coronary
artery bypass graft registry: a one-year prospective comparison with
on-pump coronary artery bypass grafting. Can J Cardiol 2005;21:
1175–81.
2. Wong DR, Agnihotri AK, Hung JW, et al. Long-term survival after
surgical revascularization for moderate ischemic mitral regurgitation.
Ann Thorac Surg 2005;80:570–8.
3. Ramsay J, Shernan S, Fitch J, et al. Increased creatine kinase MB level
predicts postoperative mortality after cardiac surgery independent of
new Q waves. J Thorac Cardiovasc Surg 2005;129:300–6.
4. Dacey LJ, Likosky DS, Leavitt BJ, et al. Perioperative stroke and
long-term survival after coronary bypass graft surgery. Ann Thorac
Surg 2005;79:532–7.
5. Izhar U, Ad N, Rudis E, et al. When should we discontinue
antiarrhythmic therapy for atrial fibrillation after coronary artery
bypass grafting? A prospective randomized trial. J Thorac Cardiovasc
Surg 2005;129:401–6.
6. Mercado N, Wijns W, Serruys PW, et al. One-year outcomes of
coronary artery bypass graft surgery versus percutaneous coronary
intervention with multiple stenting for multisystem disease: a meta-
analysis of individual patient data from randomized clinical trials.
J Thorac Cardiovasc Surg 2005;130:512–9.
7. Surruys PW, Ong ATL, van Herwerden LA, et al. Five-year outcomes
after coronary stenting versus bypass surgery for the treatment of
multivessel disease. The final analysis of the Arterial Revascularization
Therapies Study (ARTS) randomized trial. J Am Coll Cardiol
2005;46:575–81.
8. Hannan EL, Racz MJ, Walford G, et al. Long-term outcomes of
coronary artery bypass grafting versus stent implantation. N Engl
J Med 2005;352:12–21.
23
3
3
3
3
3
3
3
3
3
4
4
4
4
2107JACC Vol. 47, No. 10, 2006 Jones
May 16, 2006:2094–107 Year in Cardiovascular Surgery9. Pellika PA, Sarano ME, Nishimura RA, et al. Outcome of 622 adults
with asymptomatic, hemodynamically significant aortic stenosis during
prolonged follow-up. Circulation 2005;111:3290–5.
0. Enriquez-Sarano M, Avierinos JF, Messika-Zeitoun, et al. Quantita-
tive determinants of the outcome of asymptomatic mitral regurgita-
tion. N Engl J Med 2005;352:875–83.
1. Wu AH, Aaronson KD, Bolling SF, Pagani FD, Welch K, Koelling
TM. Impact of mitral valve annuloplasty on mortality risk in patients
with mitral regurgitation and left ventricular systolic dysfunction. J Am
Coll Cardiol 2005;45:381–7.
2. Ambler G, Omar RZ, Royston P, Kinsman R, Keogh BE, Taylor
KM. Generic, simple risk stratification model for heart valve surgery.
Circulation 2005;112:224–31.
3. Taylor NE, O’Brien SO, Edwards FH, Peterson ED, Bridges CR.
Relationship between race and mortality and morbidity after valve
replacement surgery. Circulation 2005;111:1305–12.
4. Potter DD, Sundt TM, Zehr KJ, et al. Operative risk of reoperative
aortic valve replacement. J Thorac Cardiovasc Surg 2005;129:94–103.
5. Blot WJ, Ibrahim MA, Ivey TD, et al. Twenty-five-year experience
with the Björk-Shiley convexoconcave heart valve. A continuing
clinical concern. Circulation 2005;111:2850–7.
6. Koch CG, Khandwala F, Estafanous FG, Loop FD, Blackstone EH.
Impact of prosthesis-patient size on functional recovery after aortic
valve replacement. Circulation 2005;111:3221–9.7. Doukas G, Samani NJ, Alexiou C, et al. Left atrial radiofrequency
ablation during mitral valve surgery for continuous atrial fibrillation. A
randomized controlled trial. JAMA 2005;294:2323–9.
8. Woo A, Williams WG, Choi R, et al. Clinical and echocardiographic
determinants of long-term survival after surgical myectomy in obstruc-
tive hypertrophic cardiomyopathy. Circulation 2005;111:2033–41.
9. Ralph-Edwards A, Woo A, McCrindle BW, et al. Hypertrophic
obstructive cardiomyopathy: comparison of outcomes after myectomy
or alcohol ablation adjusted by propensity score. J Thorac Cardiovasc
Surg 2005;129:351–8.
0. Mou SS, Giroir BP, Molitor-Kirsh EA, et al. Fresh whole blood
versus reconstituted blood for pump priming in heart surgery in
infants. N Engl J Med 2004;351:1635–44.
1. Zhang A, Wang S, Le Q, et al. Capillary leak syndrome in children
with C4A-deficiency undergoing cardiac surgery with cardiopulmo-
nary bypass: a double-blind, randomised controlled study. Lancet
2005;366:556–62.
2. Checchia PA, McCollegan J, Daher N, Kolovos N, Levy F, Markovitz
B. The effect of surgical case volume on outcome after the Norwood
procedure. J Thorac Cardiovasc Surg 2005;129:754–9.
3. Pedra SRFF, Pedra CAC, Abizaid AA, Braga SLN, et al. Intracoro-
nary ultrasound assessment late after the arterial switch operations for
transposition of the great arteries. J Am Coll Cardiol 2005;45:2061–8.
